氟沙那韦钙

<11

每天两次，每次45 mg / kg

每天两次7 mg / kg

11至<15

每天两次30 mg / kg

每天两次3 mg / kg

15至<20

每天两次23 mg / kg

每天两次3 mg / kg

≥20

每天两次18 mg / kg

每天两次3 mg / kg

<11

每天两次，每次45 mg / kg

每天两次7 mg / kg

11至<15

每天两次30 mg / kg

每天两次3 mg / kg

15至<20

每天两次23 mg / kg

每天两次3 mg / kg

≥20

每天两次18 mg / kg

每天两次3 mg / kg

阿巴卡韦

使用安普那韦的研究表明药代动力学相互作用不太可能¹

体外抗逆转录病毒协同作用的证据¹

阿夫唑嗪

阿夫唑嗪浓度升高可能导致低血压¹

禁忌与福沙那韦（有或无低剂量利托那韦）同时使用¹

抗酸剂

降低氨普那韦浓度和AUC ¹

fosamprenavir的制造商声明相互作用在临床上不重要，并且对与抗酸剂同时使用没有限制²

一些专家建议在抗酸剂²⁰⁰之前或之前至少2小时或之后1小时同时服用fosamprenavir

抗心律失常药（胺碘酮，决奈达隆，氟卡尼，全身性利多卡因，普罗帕酮，奎尼丁）

抗心律失常药的浓度可能会增加¹

潜力，如果患者使用利托那韦，推动福沙严重或危及生命的影响（例如，心律失常）接受氟卡尼或普罗帕酮¹

潜力如果与胺碘酮，全身利多卡因一起使用福沙那韦，或¹奎尼丁严重或危及生命的效果（例如，心律不齐）

在接受利托那韦增强的磷氨普利那韦的患者中，禁忌与氟卡尼德或普罗帕酮并用¹

谨慎地将磷氨普那韦与胺碘酮，全身性利多卡因或奎尼丁同时使用；抗心律失常浓度监测推荐¹

胺碘酮或决奈达隆：一些专家指出，它不能与磷沙那韦（有或没有低剂量的利托那韦）同时使用²⁰⁰

口服抗凝剂

阿哌沙班，依多沙班，利伐沙班：增加抗凝剂浓度²⁰⁰

达比加群：可能增加达比加群浓度²⁰⁰

华法林：可能改变的华法林浓度¹

阿pixaban，edoxaban，rivaroxaban：避免同时使用²⁰⁰

达比加群：Cl _cr > 50 mL / min的患者无需调整剂量； ²⁰⁰避免在Cl _cr <50 mL / min的患者中同时使用²⁰⁰

华法林：监测INR， ¹特别是在开始或中止fosamprenavir时； ²⁰⁰根据需要调整华法林剂量²⁰⁰

抗惊厥药（卡马西平，ethosuximide，拉莫三嗪，苯巴比妥，苯妥英钠）

卡马西平，苯巴比妥，苯妥英：可能降低安普那韦的浓度，并用未放大福沙^{1 200}使用时降低病毒学应答

卡马西平，苯巴比妥：与利托那韦增强的fosamprenavir ²⁰⁰一起使用时，卡马西平浓度可能升高而氨普那韦浓度降低

乙乙酰亚胺：可能增加乙乙酰亚胺的浓度²⁰⁰

拉莫三嗪：如果与利托那韦增强的fosamprenavir ²⁰⁰并用，拉莫三嗪浓度可能降低

苯妥英钠：当用于增加安普那韦浓度和降低的苯妥英的浓度利托升压福沙^{1 200}

卡马西平，苯巴比妥，苯妥英钠：与未加药的磷氨普钠同时使用时要谨慎； ¹一些专家指出不要与未经增强的fosamprenavir ^200并用

卡马西平，苯巴比妥：如果使用利托那韦增强的磷普仑那韦，请考虑使用其他抗惊厥药或监测抗惊厥药和安普那韦的浓度并评估抗逆转录病毒反应²⁰⁰

乙乙酰亚胺：监测乙乙酰亚胺的毒性²⁰⁰

拉莫三嗪：如果与利托那韦增强的磷氨普那韦一起使用，应考虑增加拉莫三嗪的剂量并监测拉莫三嗪的浓度； ²⁰⁰ ，考虑使用其他抗惊厥药²⁰⁰

苯妥英钠：利托那韦，福沙那韦升压的通常剂量可被使用，但根据需要^{1 200}监视器苯妥英的浓度和增加苯妥英剂量

抗真菌药，唑类（伊曲康唑，异氟康唑鎓，酮康唑，泊沙康唑，伏立康唑）

伊曲康唑：可能增加抗真菌剂和安普那韦浓度^{1 200}

Isavuconazonium（isavuconazole的前药）：如果与fosamprenavir（无低剂量ritonavir）并用，可能会增加isavuconazole的浓度并改变fosamprenavir的浓度²⁰⁰

酮康唑：可能会增加下列药物的浓度：氟沙那韦（含或不含低剂量利托那韦） ¹

泊沙康唑：与氟沙那韦（不使用低剂量利托那韦）同时使用时，泊沙康唑的AUC降低，氨普那韦浓度升高； ²⁰⁰与利托那韦，福沙那韦升压²⁰⁰中使用时，泊沙康唑增加和安普那韦浓度

伏立康唑：虽然尚无与利托那韦增强的磷氨苯丙酸相互作用的具体数据，但使用低剂量利托那韦和伏立康唑的研究表明伏立康唑的浓度降低。另外还有^{9 200} ，fosamprenavir（无小剂量利托那韦）可能会导致两种药物的浓度增加²⁰⁰

伊曲康唑：在接受氟沙那韦（有或无低剂量利托那韦）的患者中，应考虑监测伊曲康唑的浓度以指导剂量调整；在那些接受氟沙那韦（无低剂量利托那韦）治疗的患者中，可能需要减少每天接受> 400 mg伊曲康唑的患者的抗真菌剂量； ^{1 200}在那些接受利托升压福沙那韦，伊曲康唑剂量>每日不建议200毫克除非血浆浓度监测^{1 200}

Isavuconazonium：如果与fosamprenavir（有或没有低剂量的ritonavir）一起使用，请考虑监测Isavuconazole的浓度并监测与fosamprenavir相关的不良反应和病毒学应答²⁰⁰

酮康唑：在接受氟沙那韦（无低剂量利托那韦）的患者中，对于每天接受> 400 mg酮康唑的患者，可能需要降低抗真菌剂量； ¹在接受利托那韦强化的磷氨普利那韦的患者中，应谨慎使用，并建议酮康唑的剂量> 200毫克/天（不推荐使用） ¹

泊沙康唑：如果与氟沙那那韦（无小剂量利托那韦）一起使用，应监测泊沙康唑的浓度； ²⁰⁰如果与利托那韦增强的fosamprenavir一起使用，请考虑监测泊沙康唑的浓度并监测与fosamprenavir相关的不良反应²⁰⁰

伏立康唑：与福沙普那韦（无小剂量利托那韦）合用时监测毒性； ^{9 200}请勿与利托那韦增强的磷酰胺肾上腺素一起使用，除非潜在收益大于风险； ^{9 200（}如果与利托那韦增强的磷氨苯丙酸一起使用），请考虑监测伏立康唑的浓度并相应地调整伏立康唑的剂量^{9 200}

抗分枝杆菌药（贝达喹啉，利福布汀，利福平，利福喷丁）

贝达喹啉：苯达喹啉浓度可能增加； ²⁰⁰临床意义不明²⁰⁰

利福布汀：与单独使用利福布汀每天300 mg相比，每隔150 mg利托那韦增强的fosamprenavir导致氨普那韦浓度增加和利福布汀代谢产物浓度增加¹

利福平：使用安普那韦的研究表明安普那韦浓度降低； ¹可能降低抗逆转录病毒疗效并增加抗逆转录病毒耐药性的风险¹

利福喷汀：可能降低磷酰胺肾上腺素的浓度²⁰⁰

贝达喹啉：谨慎地与利托那韦增强的磷沙芬那韦合用，且前提是潜在利益大于风险。 ²⁰⁰监测QT _c间隔延长和肝功能不全²⁰⁰

利福布汀：如果将磷非那韦（无低剂量利托那韦）与利福布汀一起使用，应将利福布汀的剂量减少至少50％ ¹ （建议每日一次150 mg或每周3次300 mg）； ²⁰⁰如果与利福布汀使用利托那韦，福沙那韦升压，通过减少至少75％利福布汀剂量（150毫克每隔一天一次或每周3次最大剂量）; ^1个监视器²⁰⁰用于通过每周和临床指征进行CBCS中性白细胞减少症; ^1台抗分枝杆菌反应监测仪，并考虑对治疗药物进行监测²⁰⁰

利福平：禁忌¹

利福喷丁：不建议同时使用²⁰⁰

抗血小板药（替卡格雷，vorapaxar）

替卡格雷（voricaxar）：抗血小板药的预期浓度增加²⁰⁰

替卡格雷（voricaxar）：避免同时使用²⁰⁰

抗精神病药（鲁拉西酮，奋乃静，匹莫齐德，喹硫平，利培酮，硫代哒嗪）

鲁拉西：如果与利托那韦，推动福沙¹同时使用潜在的严重和/或危及生命的不良影响

奋乃静，利培酮，硫代哒嗪：如果与利托那韦增强的fosamprenavir ²⁰⁰并用可能增加抗精神病药的浓度

Pimozide：可能增加pimozide的浓度； ¹具有严重和/或威胁生命的作用（例如，心律不齐）的潜力¹

喹硫平：增加喹硫平浓度预期的^{1 200}

卢拉西酮：禁忌与利托那韦增强的磷酰胺肾上腺素合用； ¹如果需要与未增强的磷酰胺肾上腺素同时使用，请减少卢拉西酮的剂量¹

奋乃静，利培酮，硫代哒嗪：如果与利托那韦增强的磷氨苯丙酸一起使用，应以最低剂量开始抗精神病药并调整维持剂量； ²⁰⁰监测与抗精神病药²⁰⁰相关的毒性

Pimozide：禁忌同时使用¹

喹硫平：以最低剂量开始喹硫平，并根据需要滴定；如果在接受喹硫平的患者中开始使用福沙那韦（有或无低剂量的利托那韦），请将喹硫平减少至原始剂量的六分之一；监视喹硫平^{1 200}的功效和副作用

阿扎那韦

Ritonavir增强的fosamprenavir：阿扎那韦浓度和AUC降低；安普那韦浓度和AUC ¹无变化

Fosamprenavir（无小剂量利托那韦）：无数据¹

体外抗逆转录病毒协同作用的证据¹

福沙那韦（具有或不具有低剂量利托那韦）：适当的剂量用于伴随使用相对于安全性和有效性不成立^{1 200}

阿瓦那非

可能增加avanafil浓度和AUC如果与福沙伴随使用（具有或不具有低剂量利托那韦^{）188 200}

如果阿伐那非用于治疗勃起功能障碍，则每24小时一次不得超过阿伐那非50毫克的剂量； ^{188 200}与利托那韦，推动福沙同时使用不推荐²⁰⁰

β-肾上腺素能阻断剂（阿替洛尔，拉贝洛尔，美托洛尔，那多洛尔，索他洛尔，噻吗洛尔）

美托洛尔，噻吗洛尔：可能会增加β受体阻滞剂^200的浓度

美托洛尔，噻吗洛尔：根据临床反应，可能需要降低β受体阻滞剂的剂量； ²⁰⁰考虑使用某些未被CYP同工酶代谢的β受体阻滞剂（例如阿替洛尔，拉贝洛尔，纳多洛尔，索他洛尔） ²⁰⁰

苯二氮卓类药物（阿普唑仑，氯硝西am，氯硝西ate，地西epa，氟拉西m，咪达唑仑，三唑仑）

咪达唑仑或三唑仑：可能增加咪达唑仑或三唑仑的浓度；具有严重和/或威胁生命的作用（例如，长时间或增加的镇静作用或呼吸抑制）的潜力¹

其他苯二氮卓：阿普唑仑，氯硝西泮，氯氮卓，地西泮的可能的浓度升高，氟西泮^{1 200}

咪达唑仑或三唑仑：fosamprenavir的生产商声明禁忌同时使用； ¹一些专家指出，咪达唑仑的单剂非肠道剂量可在监测情况下谨慎用于程序镇静； ²⁰⁰考虑通过非CYP途径代谢的另一种苯二氮卓类药物（例如劳拉西m，奥沙西m，替马西m） ²⁰⁰

其他苯二氮卓类药物：药代动力学相互作用的临床重要性未知；可能需要减少苯二氮卓的剂量¹

波森坦

波生坦浓度增加¹

对于已经接受过磷磷戊酸（有或无低剂量利托那韦）治疗≥10天的患者，根据个人耐受性，每天或隔天一次使用62.5 mg剂量开始使用波生坦^{1 200}

对于已经接受过波生坦治疗的患者，应在开始服用磷沙那韦（使用或不使用低剂量利托那韦）之前中断波生坦治疗至少36小时；后福沙的≥10天，恢复使用波生坦62.5毫克每日一次或隔日一次的剂量根据个人的耐受性^{1 200}

丁丙诺啡

没有临床上重要的药代动力学相互作用²⁰⁰

Ritonavir增强的fosamprenavir：无需调整剂量。建议进行^200次临床监测； ²⁰⁰ if route of buprenorphine administration changed from transmucosal to subdermal implantation, monitor patient to ensure effect of buprenorphine is adequate and not excessive ²⁰⁰

Buspirone

Increased buspirone concentrations expected ²⁰⁰

Use low dosage of buspirone with caution and titrate based on clinical response ²⁰⁰

Calcium-channel blocking agents (diltiazem, felodipine, nifedipine, nicardipine, nimodipine, verapamil, amlodipine, nisoldipine, isradipine)

Possible increased concentrations of calcium-channel blocking agent ¹

Use concomitantly with caution; clinical monitoring recommended ¹

西沙必利

Possible increased cisapride concentrations; potential for serious and/or life-threatening effects (eg, cardiac arrhythmias) ¹

禁止同时使用¹

克拉霉素

Ritonavir-boosted fosamprenavir: Possible increased clarithromycin concentrations ²⁰⁰

Studies using amprenavir indicate increased amprenavir concentrations and AUC and slightly decreased clarithromycin concentrations ¹

Fosamprenavir (without low-dose ritonavir): Dosage adjustment not needed ²⁰⁰

Ritonavir-boosted fosamprenavir: Consider alternative macrolide (eg, azithromycin); ²⁰⁰ if used concomitantly, monitor for clarithromycin-related toxicities ²⁰⁰

Ritonavir-boosted fosamprenavir: Some experts recommend reduce clarithromycin dosage by 50% if Cl _cr 30–60 mL/minute and reduce by 75% if Cl _cr <30 mL/minute ¹

秋水仙碱

Increased colchicine concentrations ¹

Patients with renal or hepatic impairment: Concomitant use of colchicine and ritonavir-boosted fosamprenavir not recommended ¹

Colchicine for treatment of gout flares: In those receiving ritonavir-boosted fosamprenavir, use initial colchicine dose of 0.6 mg followed by 0.3 mg 1 hour later and repeat dose no earlier than 3 days later; in those receiving fosamprenavir (without low-dose ritonavir), use initial colchicine dose of 1.2 mg and repeat dose no earlier than 3 days later ¹

Colchicine for prophylaxis of gout flares: In those receiving ritonavir-boosted fosamprenavir, decrease colchicine dosage to 0.3 mg once daily in those originally receiving 0.6 mg twice daily or decrease dosage to 0.3 mg once every other day in those originally receiving 0.6 once daily; ¹ in those receiving fosamprenavir (without low-dose ritonavir), decrease colchicine dosage to 0.3 mg twice daily or 0.6 mg once daily in those originally receiving 0.6 mg twice daily or decrease dosage to 0.3 mg once daily in those originally receiving 0.6 mg once daily ¹

Colchicine for treatment of familial Mediterranean fever (FMF): In those receiving ritonavir-boosted fosamprenavir, use maximum colchicine dosage of 0.6 mg daily (may be given as 0.3 mg twice daily); ¹ in those receiving fosamprenavir (without low-dose ritonavir), use maximum colchicine dosage of 1.2 mg daily (may be given as 0.6 mg twice daily) ¹

Corticosteroids (beclomethasone, budesonide, dexamethasone, fluticasone, methylprednisolone, prednisolone, prednisone, triamcinolone)

Beclomethasone (orally inhaled, intranasal): Clinically important pharmacokinetic interactions not expected ²⁰⁰

Budesonide or fluticasone (orally inhaled, intranasal): Increased corticosteroid concentrations; ^{1 200} may result in adrenal insufficiency, including Cushing's syndrome ²⁰⁰

Methylprednisolone, prednisolone, triamcinolone (intra-articular or other local injections): Increased corticosteroid concentrations; ²⁰⁰ may result in adrenal insufficiency, including Cushing's syndrome ²⁰⁰

Budesonide or prednisone (systemic): Increased corticosteroid concentrations; ²⁰⁰ may result in adrenal insufficiency, including Cushing's syndrome ²⁰⁰

Dexamethasone (systemic): Possible decreased amprenavir concentrations and decreased antiretroviral efficacy ^{1 200}

Budesonide or fluticasone (orally inhaled, intranasal): Do not use concomitantly unless potential benefits of inhaled corticosteroid outweigh risks of systemic corticosteroid adverse effects; ²⁰⁰ consider alternative (eg, beclomethasone), ^{1 200} especially when long-term corticosteroid use anticipated ¹

Methylprednisolone, prednisolone, triamcinolone (intra-articular or other local injections): Do not use concomitantly; consider alternative nonsteroidal therapies; if intra-articular corticosteroid required, use alternative antiretroviral that does not alter CYP3A4 activity (eg, dolutegravir, raltegravir) ²⁰⁰

Budesonide or prednisone (systemic): Do not use concomitantly unless potential benefits outweigh risks of systemic corticosteroid adverse effects ²⁰⁰

Dexamethasone (systemic): Use concomitantly with caution; ^{1 200} consider alternative corticosteroid for long-term use ²⁰⁰

达卡他韦

No effect on daclatasvir concentrations if used concomitantly with fosamprenavir (with or without low-dose ritonavir) ²⁰⁰

Dosage adjustments not needed ^{178 200}

达鲁纳韦

Data not available regarding concomitant use of darunavir and fosamprenavir (with or without low-dose ritonavir) ²⁰⁰

德拉维定

Studies using amprenavir indicate possible increased amprenavir concentrations and AUC and possible decreased delavirdine plasma concentrations and AUC; ¹ possible decreased antiretroviral efficacy and increased risk of antiretroviral resistance ¹

In vitro evidence of synergistic antiretroviral effects ¹

禁止同时使用¹

Didanosine

In vitro evidence of synergistic antiretroviral effects ¹

杜鲁格韦

Ritonavir-boosted fosamprenavir: Decreased dolutegravir concentrations and AUC; ^{1 200 236} effect on fosamprenavir pharmacokinetics unlikely ²³⁶

No in vitro evidence of antagonistic antiretroviral effects with amprenavir ²³⁶

Ritonavir-boosted fosamprenavir: In integrase strand transfer inhibitor-naive (INSTI-naive) patients, use dolutegravir 50 mg twice daily; ^{1 200 236} in INSTI-experienced patients with documented or suspected INSTI resistance, consider alternative to ritonavir-boosted fosamprenavir whenever possible ^{1 200 236}

依法韦伦茨

Substantially decreased amprenavir concentrations if used with fosamprenavir (without low-dose ritonavir); ¹ additional pharmacokinetic interactions if used with ritonavir-boosted fosamprenavir ¹

In vitro evidence of synergistic antiretroviral effects ¹

Fosamprenavir (without low-dose ritonavir): Appropriate dosages for concomitant use with respect to safety and efficacy not established ¹

Ritonavir-boosted fosamprenavir: Use usual efavirenz dosage with fosamprenavir 1.4 g once daily and ritonavir 300 mg once daily or, alternatively, fosamprenavir 700 mg twice daily and ritonavir 100 mg twice daily ^{1 200}

Elbasvir and grazoprevir

Fixed combination of elbasvir and grazoprevir (elbasvir/grazoprevir): No data ²⁰⁰

艾格列韦

Cobicistat-boosted elvitegravir: Altered concentrations of elvitegravir, cobicistat, and/or fosamprenavir if used with fosamprenavir (with or without low-dose ritonavir) ²⁰⁰

Cobicistat-boosted elvitegravir: Do not used concomitantly with fosamprenavir (with or without low-dose ritonavir) ²⁰⁰

依普利农

Increased eplerenone concentrations expected ²⁰⁰

Experts state concomitant use contraindicated ²⁰⁰

Ergot alkaloids (dihydroergotamine, ergotamine, methylergonovine)

Possible increased concentrations of ergot alkaloids and potential for serious and/or life-threatening effects such as ergot toxicity (peripheral vasospasm and ischemia of the extremities and other tissues) ¹

禁止同时使用¹

If treatment of uterine atony and excessive postpartum bleeding is indicated in a woman receiving fosamprenavir, use methylergonovine maleate (Methergine ) only if alternative treatments cannot be used and if potential benefits outweigh risks; use methylergonovine at lowest dosage and shortest duration possible ²⁰²

Estrogens/progestins

Hormonal contraceptive containing ethinyl estradiol 35 mcg with norethindrone 0.5 mg per tablet: Decreased ethinyl estradiol and norethindrone concentrations with ritonavir-boosted fosamprenavir; clinically important increase in serum transaminase concentrations ¹

Hormonal contraceptives: Possible loss of virologic response if used with fosamprenavir (without low-dose ritonavir) ¹

Subdermal implants containing etonogestrel, transdermal systems containing ethinyl estradiol and norelgestromin: No data ²⁰⁰

Hormonal contraceptives: Consider alternative or additional contraception methods or consider alternative antiretroviral regimen ^{1 200}

Subdermal implants containing etonogestrel, transdermal systems containing ethinyl estradiol and norelgestromin: Consider alternative or additional methods of contraception or consider alternative antiretroviral regimen ²⁰⁰

依他韦

Fosamprenavir (with or without low-dose ritonavir): Substantially increased amprenavir concentrations ²¹⁴

Fosamprenavir (with or without low-dose ritonavir): Do not administer concomitantly ²⁰⁰

氟班色林

Increased flibanserin concentrations expected ²⁰⁰

Experts state concomitant use contraindicated ²⁰⁰

氟伏沙明

Possible altered fosamprenavir concentrations ²⁰⁰

Consider alternative antidepressant or alternative antiretroviral therapy ²⁰⁰

Histamine H ₂ -receptor antagonists (cimetidine, famotidine, nizatidine, ranitidine)

Decreased amprenavir plasma concentrations and AUC; ¹ possible decreased antiretroviral efficacy ¹

Use concomitantly with caution; ¹ administer fosamprenavir (without low-dose ritonavir) at least 2 hours before the H ₂ -receptor antagonist; ²⁰⁰ consider using ritonavir-boosted fosamprenavir ²⁰⁰

HMG-CoA还原酶抑制剂（他汀类）

Atorvastatin, lovastatin, rosuvastatin, simvastatin: Increased concentrations and AUCs of the statin; increased risk of statin-associated adverse effects, including myopathy and rhabdomyolysis ^{1 186 200}

Atorvastatin: Do not exceed atorvastatin dosage of 20 mg daily in patients receiving fosamprenavir (with or without low-dose ritonavir); ^{1 186 200} carefully titrate atorvastatin dosage; use lowest necessary dosage with close monitoring for adverse effects ^{1 200}

Lovastatin: Concomitant use with fosamprenavir (with or without low-dose ritonavir) contraindicated ^{1 186 200}

Pitavastatin: Dosage adjustments not necessary ²⁰⁰

Rosuvastatin: Dosage adjustments not necessary ²⁰⁰

Simvastatin: Concomitant use with fosamprenavir (with or without low-dose ritonavir) contraindicated ^{1 186 200}

Immunosuppressive agents (cyclosporine, everolimus, sirolimus, tacrolimus)

Increased concentrations of immunosuppressive agent expected ^{1 200}

Monitor immunosuppressive agent concentrations; ^{1 200} some experts state initiate immunosuppressive agent with adjusted dosage to account for potential increased concentrations, ²⁰⁰ monitor for toxicities, ²⁰⁰ consult a specialist if needed ²⁰⁰

茚地那韦

Fosamprenavir: Possible increased amprenavir concentrations and AUC; effect on indinavir concentrations not well established ¹

Ritonavir-boosted fosamprenavir: Concomitant use not evaluated ¹

In vitro evidence of additive antiretroviral effects ¹

Fosamprenavir (with or without low-dose ritonavir): Appropriate dosages for concomitant use with respect to safety and efficacy not established ¹

伊伐布雷定

Increased ivabradine concentrations expected ²⁰⁰

Experts state concomitant use contraindicated ²⁰⁰

Lamivudine

Studies using amprenavir indicate no evidence of pharmacokinetic interaction ¹

In vitro evidence of synergistic antiretroviral effects ¹

Ledipasvir and sofosbuvir

Fixed combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir): Pharmacokinetic interactions not expected if used concomitantly with fosamprenavir (with or without low-dose ritonavir) ²⁰⁰

Concomitant use of ledipasvir/sofosbuvir and HIV antiretroviral regimen that includes ritonavir-boosted fosamprenavir and tenofovir DF: Possible increased tenofovir concentrations; ^{181 200} safety of increased tenofovir concentrations not established ^{181 200}

Ledipasvir/sofosbuvir: Dosage adjustments not needed if used concomitantly with fosamprenavir (with or without low-dose ritonavir) ²⁰⁰

Concomitant use of ledipasvir/sofosbuvir and HIV antiretroviral regimen that includes ritonavir-boosted fosamprenavir and tenofovir DF: Consider alternative HCV treatment or an alternative antiretroviral regimen; ^{181 200} if concomitant use necessary, monitor patient for tenofovir-associated adverse effects ^{181 200}

洛匹那韦/利托那韦

Fosamprenavir: Decreased amprenavir concentrations and AUC; no change in lopinavir concentrations or AUC ¹

Ritonavir-boosted fosamprenavir: Decreased amprenavir concentrations and AUC; altered lopinavir concentrations and AUC (decreased or increased) ¹

Increased incidence of adverse effects reported ¹

In vitro evidence of additive antiretroviral effects ¹

Fosamprenavir (with or without low-dose ritonavir): Concomitant use not recommended; ²⁰⁰ appropriate dosages for concomitant use with respect to safety and efficacy not established ^{1 200}

Maraviroc

Increased maraviroc concentrations and AUC; decreased amprenavir concentrations and AUC ^{1 200 224}

No in vitro evidence of antagonistic antiretroviral effects ²²⁴

Recommended maraviroc dosage is 150 mg twice daily with usual dosage of ritonavir-boosted fosamprenavir; ^{1 200 224} do not use unboosted fosamprenavir ^{1 224}

美沙酮

Decreased methadone concentrations; ¹ opiate withdrawal unlikely but may occur ²⁰⁰

Methadone dosage may need to be adjusted; ¹ monitor for opiate withdrawal and increase methadone dosage as clinically indicated ^{1 200}

奈非那韦

Studies using amprenavir indicate concomitant use may affect pharmacokinetics of both drugs; ¹ concomitant use of ritonavir-boosted fosamprenavir and nelfinavir not evaluated ¹

In vitro evidence of additive antiretroviral effects ¹

Appropriate dosages for concomitant use with respect to safety and efficacy not established ¹

奈韦拉平

Fosamprenavir (without low-dose ritonavir): Decreased amprenavir AUC and increased nevirapine AUC ¹

Ritonavir-boosted fosamprenavir (twice-daily regimen): Decreased amprenavir AUC and increased nevirapine AUC ¹

Ritonavir-boosted fosamprenavir (once-daily regimen): Concomitant use with nevirapine not studied

In vitro evidence of additive antiretroviral effects ¹

Fosamprenavir (without low-dose ritonavir): Concomitant use not recommended ¹

RItonavir-boosted fosamprenavir (twice-daily regimen): Use usual nevirapine dosage with fosamprenavir 700 mg twice daily and ritonavir 100 mg twice daily ¹

Ombitasvir, paritaprevir, ritonavir, and dasabuvir

Fosamprenavir (without low-dose ritonavir): Concomitant use with fixed combination of ombitasvir, paritaprevir, and ritonavir (ombitasvir/paritaprevir/ritonavir) with dasabuvir may result in increased paritaprevir and amprenavir concentrations ¹

Ritonavir-boosted fosamprenavir: Increased paritaprevir concentrations expected if used concomitantly with ombitasvir/paritaprevir/ritonavir with dasabuvir; ¹ possible increased amprenavir concentrations ¹

Fosamprenavir (without low-dose ritonavir): If used concomitantly with ombitasvir/paritaprevir/ritonavir with dasabuvir, dosage adjustments not established but fosamprenavir manufacturer states consider fosamprenavir 1.4 g once daily ¹

Ritonavir-boosted fosamprenavir: Concomitant use with ombitasvir/paritaprevir/ritonavir with dasabuvir not recommended ¹

Proton-pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)

Esomeprazole: When used with fosamprenavir (without low-dose ritonavir), no change in amprenavir concentrations or AUC, and increased esomeprazole AUC; ¹ when used with ritonavir-boosted fosamprenavir, clinically important pharmacokinetic interaction unlikely ¹

Can be administered at the same time as proton-pump inhibitors with no change in plasma amprenavir concentrations ¹

Dosage adjustments of fosamprenavir (with or without low-dose ritonavir) not needed ²⁰⁰

雷格列韦

Fosamprenavir (with or without low-dose ritonavir): Decreased concentrations and AUCs of raltegravir and amprenavir ¹

Fosamprenavir (with or without low-dose ritonavir): Appropriate dosage for concomitant use with respect to safety and efficacy not established; ¹ some experts state dosage adjustments not necessary ²⁰⁰

利匹韦林

Possible increased rilpivirine concentrations; not expected to affect amprenavir concentrations ²²⁶

Some experts state dosage adjustments not necessary ²⁰⁰

利托那韦

Increased plasma concentrations and AUC of amprenavir ^{1 200}

Concomitant low-dose ritonavir used for therapeutic advantage ( ritonavir-boosted fosamprenavir); ¹ increased potential for drug interactions since ritonavir is a potent inhibitor of CYP3A4 and also inhibits CYP2D6 ¹

In vitro evidence of additive antiretroviral effects ¹

When ritonavir-boosted fosamprenavir is used in a once-daily regimen, recommended dosage is fosamprenavir 1.4 g once daily with ritonavir 100 or 200 mg once daily; when used in a twice-daily regimen, recommended dosage is fosamprenavir 700 mg twice with ritonavir 100 mg twice daily ^{1 200}

Once-daily regimen of ritonavir-boosted fosamprenavir not recommended in PI-experienced patients ¹

St. John's wort ( Hypericum perforatum )

Possible decreased amprenavir concentrations; ¹ possible decreased antiretroviral efficacy and increased risk of antiretroviral resistance ¹

禁止同时使用¹

Salmeterol

Possible increased salmeterol concentrations and increased risk of salmeterol-associated adverse cardiovascular effects, including QT interval prolongation, palpitations, and sinus tachycardia ¹

不建议同时使用¹

沙奎那韦

Decreased amprenavir concentrations ¹

In vitro evidence of synergistic antiretroviral effects ¹

Appropriate dosages for concomitant use with respect to safety and efficacy not established ^{1 200}

Selective serotonin-reuptake inhibitors (SSRIs)

Paroxetine: Decreased SSRI concentrations with ritonavir-boosted fosamprenavir ¹

Paroxetine: Titrate dosage of the SSRI based on clinical response and tolerability ^{1 200}

Sildenafil

Possible increased sildenafil concentrations and increased risk of sildenafil-associated adverse effects (eg, hypotension, syncope, visual disturbances, prolonged erection) ¹

Sildenafil (Revatio ) for treatment of pulmonary arterial hypertension (PAH): Concomitant use with fosamprenavir (with or without low-dose ritonavir) is contraindicated; ^{1 200} fosamprenavir manufacturer states that a safe and effective dose for concomitant use not established ¹

Sildenafil for treatment of erectile dysfunction: If used concomitantly with fosamprenavir (with or without low-dose ritonavir), do not exceed sildenafil dosage of 25 mg once every 48 hours and closely monitor for sildenafil-associated adverse effects (eg, hypotension, syncope, visual disturbances, prolonged erection) ^{1 200}

西美普韦

Fosamprenavir (without low-dose ritonavir): Possible altered simeprevir concentrations; ^{1 187} altered amprenavir concentrations not expected ¹

Ritonavir-boosted fosamprenavir: Increased simeprevir concentrations expected; ¹ altered amprenavir concentrations not expected ¹

Concomitant use with fosamprenavir (with or without low-dose ritonavir) not recommended ^{1 187 200}

Stavudine

In vitro evidence of synergistic antiretroviral effects ¹

舒维生

Increased suvorexant concentrations expected ²⁰⁰

Experts state concomitant use not recommended ²⁰⁰

Tadalafil

Possible increased tadalafil concentrations and increased risk of tadalafil-associated adverse effects (eg, hypotension, syncope, visual disturbances, prolonged erection) ^{1 200}

If tadalafil (Adcirca ) is initiated for treatment of PAH in patients who have been receiving fosamprenavir (with or without low-dose ritonavir) for ≥1 week, use initial tadalafil dosage of 20 mg once daily and, if tolerated, increase dosage to 40 mg once daily ¹

If fosamprenavir (with or without low-dose ritonavir) is indicated in patient already receiving tadalafil (Adcirca ) for treatment of PAH, discontinue tadalafil for at least 24 hours prior to initiating fosamprenavir; after ≥1 week of the antiretroviral agent, resume tadalafil at dosage of 20 mg once daily and, if tolerated, increase dosage to 40 mg once daily ¹

If tadalafil is used for treatment of erectile dysfunction in patients already receiving fosamprenavir (with or without low-dose ritonavir), do not exceed tadalafil dosage of 10 mg once every 72 hours and closely monitor for tadalafil-related adverse effects (eg, hypotension, syncope, visual disturbances, prolonged erection, syncope) ¹

If tadalafil is used for treatment of benign prostatic hyperplasia, do not exceed tadalafi

已知总共有423种药物与fosamprenavir相互作用。

• 154种主要药物相互作用
• 247种中等程度的药物相互作用
• 22种次要药物相互作用

在数据库中显示可能与fosamprenavir相互作用的所有药物。

检查互动

输入药物名称以检查与fosamprenavir的相互作用。

最常检查的互动

查看fosamprenavir和下列药物的相互作用报告。

• Advair Diskus（氟替卡松/沙美特罗）
• 安普那韦
• Benadryl Allergy Plus窦性头痛（对乙酰氨基酚/苯海拉明/去氧肾上腺素）
• 钙600 D（钙/维生素D）
• Daliresp（罗氟司特）
• 达鲁纳韦
• Drisdol（麦角钙化醇）
• Flonase（氟替卡松鼻）
• 碘（洛哌丁胺）
• Januvia（西他列汀）
• Keflex（头孢氨苄）
• Orabase中的Kenalog（曲安西龙局部用药）
• 抒情诗（普瑞巴林）
• 马里诺尔（dronabinol）
• 诺维（利托那韦）
• Plavix（氯吡格雷）
• 制剂H最大强度（局部使用甘油/凡士林/去氧肾上腺素/普拉莫辛）
• 雷格列韦
• 利托那韦
• Symbicort（布地奈德/福莫特罗）
• Symmetrel（金刚烷胺）
• 替诺福韦
• 旋毛虫（伏地西汀）
• Truvada（恩曲他滨/替诺福韦）
• 尿酸（非布索坦）

福沙那韦酒精/食物的相互作用

fosamprenavir与酒精/食物有2种相互作用

福沙那韦病相互作用

fosamprenavir有4种疾病相互作用，包括：

• 血友病
• 肾结石症
• 高血糖症
• 高脂血症

药物状态

• 可用性 仅处方
• 怀孕和哺乳 现有风险数据
• CSA时间表* 不是管制药物
• 审批历史 FDA的药物史

相关药物

• 特鲁瓦达
• Isentress
• 苏斯蒂瓦
• 完成
• Epzicom
• Emtriva
• Atripla

美国日本医生

Heather Benjamin MD

经验：11-20年

Heather Benjamin MD

经验：11-20年

Suzanne Reitz MD

经验：11-20年

Heather Miske DO

经验：11-20年

Heather Miske DO

经验：11-20年

渡邊剛

经验：21年以上

渡邊剛

经验：21年以上

渡邊剛

经验：21年以上

宮崎総一郎 中部大学特聘教授

经验：21年以上

百村伸一 教授

经验：21年以上

临床试验

• 杜克大学脊柱结果研究（DSO）（DSO）
• 不同剂量的SY-004在2型糖尿病患者中的功效和安全性
• IP秘鲁，土豆（Ipperu）的铁生物利用度
• 光疗对血清钙的影响
• 在医疗保健索赔中复制Empareg糖尿病试验
• 通过快速评估血清BNP（Pandora）的胎盘摄入新检测程序
• 牙龈阿拉伯摄入对多囊卵巢综合征（GA＆PCO）患者激素和代谢变化的影响
• DeDidustat在透析患者的CKD治疗CKD中（Dream-D）
• 脑电图生物标志物预测急性术后认知功能障碍
• 开发用于早期差异诊断子宫平滑肌瘤和平滑肌肉瘤（Myosarc）的预测模型